Notice Concerning the Acquisition of Treasury Shares and the Cancellation of Treasury Shares
Filed with TSE · · 2 pages · English
Summary by 6ix AI
Daito Pharmaceutical Co., Ltd. has announced its plan to acquire and cancel treasury shares as part of its capital policy aimed at enhancing shareholder returns and improving capital efficiency. The company intends to acquire up to a specified number of common shares and plans to cancel an equal number of shares. The acquisition is set to take place over a defined period, with market purchases planned on the Tokyo Stock Exchange.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Daito Pharmaceutical Co., Ltd. on 6ix
In the deck
Story so far
Earlier from Daito Pharmaceutical
- Execution of JV and Share Transfer Agreement for Transfer of KYORIN Pharmaceutical's Generic Drug Business to JV by Daito, Meiji Seika Pharma and DBJ
- FY2026 4Q Earnings Presentation
- Notice Regarding the Results and Completion of the Acquisition of Treasury Shares Through Off-Auction Own Share Repurchase Transaction (ToSTNet-3)
- Summary of Consolidated Financial Results for the Fiscal Year Ended May 31,2026 (Under Japanese GAAP)
- PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer
Follow Daito Pharmaceutical into a list and get an email when it puts out news.
Follow Daito Pharmaceutical